Assaraf YG - Search Results

1

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.

Leonetti A, Wever B, Mazzaschi G, Assaraf YG, Rolfo C, Quaini F, Tiseo M, Giovannetti E. Leonetti A, et al. Among authors: assaraf yg. Drug Resist Updat. 2019 Sep;46:100644. doi: 10.1016/j.drup.2019.100644. Epub 2019 Sep 17. Drug Resist Updat. 2019. PMID: 31585395 Review.

2

The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.

Assaraf YG. Assaraf YG. Drug Resist Updat. 2006 Aug-Oct;9(4-5):227-46. doi: 10.1016/j.drup.2006.09.001. Epub 2006 Nov 7. Drug Resist Updat. 2006. PMID: 17092765 Review.

3

New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma.

Zucali PA, Giovannetti E, Assaraf YG, Ceresoli GL, Peters GJ, Santoro A. Zucali PA, et al. Among authors: assaraf yg. Ann Oncol. 2010 Jul;21(7):1560-1561. doi: 10.1093/annonc/mdq253. Epub 2010 May 5. Ann Oncol. 2010. PMID: 20447928 Free article. No abstract available.

4

Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.

Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Shapira A, et al. Among authors: assaraf yg. Drug Resist Updat. 2011 Jun;14(3):150-63. doi: 10.1016/j.drup.2011.01.003. Epub 2011 Feb 16. Drug Resist Updat. 2011. PMID: 21330184 Review.

5

Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.

Lemos C, Giovannetti E, Zucali PA, Assaraf YG, Scheffer GL, van der Straaten T, D'Incecco A, Falcone A, Guchelaar HJ, Danesi R, Santoro A, Giaccone G, Tibaldi C, Peters GJ. Lemos C, et al. Among authors: assaraf yg. Pharmacogenomics. 2011 Feb;12(2):159-70. doi: 10.2217/pgs.10.172. Pharmacogenomics. 2011. PMID: 21332310 Free PMC article.

6

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.

Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, Roncalli M, Santoro A, Peters GJ. Giovannetti E, et al. Among authors: assaraf yg. Br J Cancer. 2011 Nov 8;105(10):1542-53. doi: 10.1038/bjc.2011.400. Epub 2011 Oct 4. Br J Cancer. 2011. PMID: 21970874 Free PMC article.

7

Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.

de Wilt LH, Jansen G, Assaraf YG, van Meerloo J, Cloos J, Schimmer AD, Chan ET, Kirk CJ, Peters GJ, Kruyt FA. de Wilt LH, et al. Among authors: assaraf yg. Biochem Pharmacol. 2012 Jan 15;83(2):207-17. doi: 10.1016/j.bcp.2011.10.009. Epub 2011 Oct 18. Biochem Pharmacol. 2012. PMID: 22027222

8

Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.

Gonen N, Assaraf YG. Gonen N, et al. Among authors: assaraf yg. Drug Resist Updat. 2012 Aug;15(4):183-210. doi: 10.1016/j.drup.2012.07.002. Epub 2012 Aug 23. Drug Resist Updat. 2012. PMID: 22921318 Review.

9

The folate receptor as a rational therapeutic target for personalized cancer treatment.

Assaraf YG, Leamon CP, Reddy JA. Assaraf YG, et al. Drug Resist Updat. 2014 Oct-Dec;17(4-6):89-95. doi: 10.1016/j.drup.2014.10.002. Epub 2014 Oct 8. Drug Resist Updat. 2014. PMID: 25457975 Review.

10

The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.

Porcelli L, Giovannetti E, Assaraf YG, Jansen G, Scheffer GL, Kathman I, Azzariti A, Paradiso A, Peters GJ. Porcelli L, et al. Among authors: assaraf yg. Curr Drug Targets. 2014;15(14):1322-30. doi: 10.2174/1389450116666141205145620. Curr Drug Targets. 2014. PMID: 25479544

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

239 results

Search Page